Clinical Trials Browser

Not yet recruiting × blinatumomab × Other hematologic neoplasm × Clear all

NCT07178912 2026-03-09

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07454226 2026-03-06

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

Phase NA Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07223190 2026-03-04

AUDAX

Phase 3 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07443592 2026-03-02

LAL-2025

Phase NA Not yet recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06991920 2026-02-11

Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

Phase NA Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07387926 2026-02-04

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Phase 1/2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07283640 2025-12-22

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07192237 2025-12-18

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07227584 2025-11-12

ALL Backbone in AYAs

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06649422 2024-10-18

Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

Not yet recruiting

Other hematologic neoplasm

Leukemia

NCT06075238 2023-10-10

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Lymphoid